Identification and Validation of Prognostic Model for Tumor Microenvironment-Associated Genes in Bladder Cancer Based on Single-Cell RNA Sequencing Data Sets.


Journal

JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370

Informations de publication

Date de publication:
Aug 2024
Historique:
medline: 16 8 2024
pubmed: 16 8 2024
entrez: 16 8 2024
Statut: ppublish

Résumé

The purpose of this study was to elucidate the relationship between the tumor microenvironment (TME) and cellular diversity in bladder cancer (BLCA) progression, leveraging single-cell RNA sequencing (scRNA-seq) data to identify potential prognostic biomarkers and construct a prognostic model for BLCA. We analyzed scRNA-seq data of normal and tumor bladder cells from the Gene Expression Omnibus (GEO) database to uncover crucial markers within the bladder TME. The study compared gene expression in normal versus tumor bladder cells, identifying differentially expressed genes. These genes were subsequently assessed for their prognostic significance using patient follow-up data from The Cancer Genome Atlas. Prognostic models were constructed using Least Absolute Shrinkage and Selection Operator and multivariate Cox regression analyses, focusing on eight genes of interest. The predictive performance of the model was also tested against additional GEO data sets (GSE31684, GSE13507, and GSE32894). The prognostic model demonstrated reliable prediction of patient outcomes. Validation through gene set enrichment analysis and immune cell infiltration assessment supported the model's efficacy. The results from both the univariate and multivariate analyses suggest that the risk score is an independent prognostic factor with a hazard ratio of 2.97 (95% CI, 2.28 to 3.9, Our findings proposed biomarkers with prognostic potential, laying the groundwork for future in vitro validation and therapeutic exploration. This contributes to a deeper understanding of the genes associated with bladder TME and may improve prognostic precision in BLCA management.

Identifiants

pubmed: 39151107
doi: 10.1200/PO.23.00661
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2300661

Auteurs

Imran Safder (I)

Case Western Reserve School of Medicine, Cleveland, OH.

Henkel Valentine (H)

Fox Chase Cancer Center, Philadelphia, PA.

Nicole Uzzo (N)

Fox Chase Cancer Center, Philadelphia, PA.

John Sfakianos (J)

Mount Sinai Medical Center, New York, NY.

Robert Uzzo (R)

Fox Chase Cancer Center, Philadelphia, PA.

Shilpa Gupta (S)

Cleveland Clinic Foundation, Cleveland, OH.

Jason Brown (J)

Case Western Reserve School of Medicine, Cleveland, OH.
University Hospitals Cleveland Medical Center, Cleveland, OH.

Daniel Ranti (D)

Mount Sinai Medical Center, New York, NY.

Elizabeth Plimack (E)

Fox Chase Cancer Center, Philadelphia, PA.

George Haber (G)

Cleveland Clinic Foundation, Cleveland, OH.

Christopher Weight (C)

Cleveland Clinic Foundation, Cleveland, OH.

Alexander Kutikov (A)

Fox Chase Cancer Center, Philadelphia, PA.

Philip Abbosh (P)

Fox Chase Cancer Center, Philadelphia, PA.
Albert Einstein Medical Center, Philadelphia, PA.

Laura Bukavina (L)

Case Western Reserve School of Medicine, Cleveland, OH.
Cleveland Clinic Foundation, Cleveland, OH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH